Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Revenue of Avadel Pharmaceuticals plc (AVDL)
Revenue in 2023 (TTM): $27.96 M
According to Avadel Pharmaceuticals plc's latest financial reports the company's current revenue (TTM) is $27.96 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Avadel Pharmaceuticals plc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $27.96 M | $25.35 M | $-136,083,000 | $-160,777,000 | $-160,276,000 |
| 2022 | $ | $-1,493,000 | $-93,723,000 | $-111,439,000 | $-137,464,000 |
| 2021 | $ | $-815,000 | $-84,567,000 | $-93,145,000 | $-77,329,000 |
| 2020 | $22.33 M | $16.59 M | $-31,607,000 | $-5,082,000 | $7.03 M |
| 2019 | $59.22 M | $47.09 M | $-14,340,000 | $-38,582,000 | $-33,226,000 |
| 2018 | $103.27 M | $85.75 M | $-53,124,000 | $-113,197,000 | $-95,304,000 |
| 2017 | $172.74 M | $156.44 M | $64.58 M | $91.47 M | $67.25 M |
| 2016 | $150.25 M | $137 M | $58.81 M | $-9,718,000 | $-41,276,000 |
| 2015 | $173.21 M | $162.29 M | $115.54 M | $78.39 M | $40.66 M |
| 2014 | $14.78 M | $11.39 M | $-18,285,000 | $-90,331,000 | $-84,906,000 |
| 2013 | $22.44 M | $18.09 M | $-21,325,000 | $-54,095,000 | $-42,925,000 |
| 2012 | $26.1 M | $20.24 M | $-36,387,000 | $-7,930,000 | $-3,228,000 |
| 2011 | $32.6 M | $26.32 M | $-9,990,000 | $-8,582,000 | $-8,774,000 |
| 2010 | $37.09 M | $30.18 M | $-10,474,000 | $-8,766,000 | $-8,975,000 |
| 2009 | $42.12 M | $32 M | $-11,642,000 | $-11,439,000 | $-11,439,000 |
| 2008 | $38.62 M | $29 M | $-11,479,000 | $-18,562,000 | $-12,084,000 |
| 2007 | $36.65 M | $19.33 M | $-34,394,000 | $-39,431,000 | $-37,737,000 |
| 2006 | $23.02 M | $16.77 M | $-32,731,000 | $-37,319,000 | $-35,201,000 |
| 2005 | $23.6 M | $21.07 M | $-41,529,000 | $-31,663,000 | $-27,377,000 |
| 2004 | $55.41 M | $51.81 M | $11.51 M | $9.3 M | $12.5 M |
| 2003 | $25.17 M | $21.49 M | $-3,096,000 | $-3,997,000 | $-3,494,000 |
| 2002 | $18.41 M | $16.03 M | $-1,190,000 | $2.45 M | $3.01 M |
| 2001 | $13.09 M | $10.92 M | $-1,940,000 | $-2,860,000 | $-2,874,000 |
| 2000 | $10.9 M | $9.15 M | $-15,043,000 | $-4,834,000 | $-9,461,000 |
| 1999 | $11.04 M | $8.95 M | $-5,932,000 | $-6,678,000 | $-6,694,000 |
| 1998 | $9.52 M | $5.99 M | $-8,174,000 | $-9,059,000 | $-7,812,000 |
| 1997 | $8.1 M | $5 M | $-9,000,000 | $-8,200,000 | $-6,800,000 |
| 1996 | $4.9 M | $4.5 M | $-8,800,000 | $-8,400,000 | $-6,900,000 |